Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 2
2021 2
2022 4
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Identification of FasL as a crucial host factor driving COVID-19 pathology and lethality.
Albert MC, Uranga-Murillo I, Arias M, De Miguel D, Peña N, Montinaro A, Varanda AB, Theobald SJ, Areso I, Saggau J, Koch M, Liccardi G, Peltzer N, Rybniker J, Hurtado-Guerrero R, Merino P, Monzón M, Badiola JJ, Reindl-Schwaighofer R, Sanz-Pamplona R, Cebollada-Solanas A, Megyesfalvi Z, Dome B, Secrier M, Hartmann B, Bergmann M, Pardo J, Walczak H. Albert MC, et al. Cell Death Differ. 2024 Mar 21. doi: 10.1038/s41418-024-01278-6. Online ahead of print. Cell Death Differ. 2024. PMID: 38514848
LUBAC is required for RIG-I sensing of RNA viruses.
Teague HC, Lefevre C, Rieser E, Wolfram L, de Miguel D, Patricio de Oliveira D, Oliveira M, Mansur DS, Irigoyen N, Walczak H, Ferguson BJ. Teague HC, et al. Cell Death Differ. 2024 Jan;31(1):28-39. doi: 10.1038/s41418-023-01233-x. Epub 2023 Nov 24. Cell Death Differ. 2024. PMID: 38001254 Free PMC article.
Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.
Malchers F, Nogova L, van Attekum MH, Maas L, Brägelmann J, Bartenhagen C, Girard L, Bosco G, Dahmen I, Michels S, Weeden CE, Scheel AH, Meder L, Golfmann K, Schuldt P, Siemanowski J, Rehker J, Merkelbach-Bruse S, Menon R, Gautschi O, Heuckmann JM, Brambilla E, Asselin-Labat ML, Persigehl T, Minna JD, Walczak H, Ullrich RT, Fischer M, Reinhardt HC, Wolf J, Büttner R, Peifer M, George J, Thomas RK. Malchers F, et al. J Clin Invest. 2023 Nov 1;133(21):e170217. doi: 10.1172/JCI170217. J Clin Invest. 2023. PMID: 37606995 Free PMC article.
Cleavage of cFLIP restrains cell death during viral infection and tissue injury and favors tissue repair.
Martinez Lagunas K, Savcigil DP, Zrilic M, Carvajal Fraile C, Craxton A, Self E, Uranga-Murillo I, de Miguel D, Arias M, Willenborg S, Piekarek M, Albert MC, Nugraha K, Lisewski I, Janakova E, Igual N, Tonnus W, Hildebrandt X, Ibrahim M, Ballegeer M, Saelens X, Kueh A, Meier P, Linkermann A, Pardo J, Eming S, Walczak H, MacFarlane M, Peltzer N, Annibaldi A. Martinez Lagunas K, et al. Sci Adv. 2023 Jul 28;9(30):eadg2829. doi: 10.1126/sciadv.adg2829. Epub 2023 Jul 26. Sci Adv. 2023. PMID: 37494451 Free PMC article.
A preclinical platform for assessing antitumor effects and systemic toxicities of cancer drug targets.
Li X, Huang CH, Sánchez-Rivera FJ, Kennedy MC, Tschaharganeh DF, Morris JP 4th, Montinaro A, O'Rourke KP, Banito A, Wilkinson JE, Chen CC, Ho YJ, Dow LE, Tian S, Luan W, de Stanchina E, Zhang T, Gray NS, Walczak H, Lowe SW. Li X, et al. Proc Natl Acad Sci U S A. 2022 Apr 26;119(17):e2110557119. doi: 10.1073/pnas.2110557119. Epub 2022 Apr 20. Proc Natl Acad Sci U S A. 2022. PMID: 35442775 Free PMC article.
Compound heterozygous variants in OTULIN are associated with fulminant atypical late-onset ORAS.
Zinngrebe J, Moepps B, Monecke T, Gierschik P, Schlichtig F, Barth TFE, Strauß G, Boldrin E, Posovszky C, Schulz A, Beringer O, Rieser E, Jacobsen EM, Lorenz MR, Schwarz K, Pannicke U, Walczak H, Niessing D, Schuetz C, Fischer-Posovszky P, Debatin KM. Zinngrebe J, et al. EMBO Mol Med. 2022 Mar 7;14(3):e14901. doi: 10.15252/emmm.202114901. Epub 2022 Feb 16. EMBO Mol Med. 2022. PMID: 35170849 Free PMC article.
Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers.
Montinaro A, Areso Zubiaur I, Saggau J, Kretz AL, Ferreira RMM, Hassan O, Kitzig E, Müller I, El-Bahrawy MA, von Karstedt S, Kulms D, Liccardi G, Lemke J, Walczak H. Montinaro A, et al. Cell Death Differ. 2022 Mar;29(3):492-503. doi: 10.1038/s41418-021-00869-x. Epub 2021 Sep 17. Cell Death Differ. 2022. PMID: 34535764 Free PMC article.
15 results